Akeso：Gumokimab was approved
On June 11, the NMPA official website showed that Akeso’s Gumokimab has been approved for marketing for the first time in China for the treatment of moderate-to-severe plaque psoriasis. Notably, this is the second innovative drug in the autoimmune disease field approved by Akeso, following Etanokimab, marking an important breakthrough for Akeso beyond the oncology therapeutic area. With this approval, Gumokimab and Etanokimab can form a strategic combination to address differentiated treatment needs for psoriasis, further enhancing Akeso’s overall product synergy in the autoimmune disease space.
IL-17 (interleukin-17) is a pro-inflammatory cytokine primarily secreted by activated Th17 cells (helper T cells 17). After binding to cell surface receptors (IL-17R), it mediates immune inflammatory responses and plays a key role in the pathogenesis of psoriasis and ankylosing spondylitis.
Gumokimab (development code: AK111) is a novel humanized IL-17A monoclonal antibody independently developed by Akeso. In January 2025, Akeso submitted its first New Drug Application (NDA) for Gumokimab in China; subsequently, in January 2026, a second indication NDA for the treatment of ankylosing spondylitis was also accepted by the CDE.
Buy Gumokimab from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
